Harmony Biosciences (HRMY) News Today

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at Cantor Fitzgerald cut their FY2024 EPS estimates for shares of Harmony Biosciences in a research note issued to investors on Wednesday, July 24th. Cantor Fitzgerald analyst C. Duncan now forecasts that the co

LSV Asset Management grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 346.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 335,146 shares of

Harmony Biosciences (NASDAQ:HRMY) Stock Price Up 4.1%

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation an

Hedeker Wealth LLC bought a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 78,223 shares of the company's stock, valued

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 EPS estimates for Harmony Biosciences in a research report issued to clients and investors on Monday, July 1st. Cantor Fitzgerald analyst C. Duncan now anticipates tha

Harmony Biosciences (NASDAQ:HRMY) Stock Price Down 2.9%

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 8,130,000 shares, a growth of 17.1% from the May 31st total of 6,940,000 shares. Based on an average trading volume of 383,000 shares, the days-to-cover ratio is presently 21.2 days. Approximately 26.5% of the shares of the stock are sold short.

Needham & Company LLC reissued a "buy" rating and set a $52.00 target price on shares of Harmony Biosciences in a report on Monday.

Citigroup initiated coverage on shares of Harmony Biosciences in a report on Friday. They set a "buy" rating and a $48.00 price objective on the stock.

Franklin Resources Inc. bought a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 27,136 shares of the company's stock, valued at approximately $876,0

Dimensional Fund Advisors LP reduced its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 736,268 shares of the compa

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 7,090,000 shares, an increase of 5.5% from the April 30th total of 6,720,000 shares. Approximately 23.1% of the shares of the company are sold short. Based on an average trading volume of 415,000 shares, the short-interest ratio is presently 17.1 days.

Charles Schwab Investment Management Inc. boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 9.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,167 shares of the company's sto

Great Lakes Advisors LLC lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 49.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 141,301 shares of the company's stock after selling 139,867 shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and six have

LSV Asset Management bought a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 75,053 shares of the company's stock, va

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) released its quarterly earnings results on Tuesday. The company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.07. Harmony Biosciences had a return on equity of 27.49% and a net margin of 22.16%. The company had revenue of $154.62 million for the quarter, compared to analysts' expectations of $154.10 million. During the same period in the prior year, the firm earned $0.48 earnings per share. The firm's revenue was up 29.8% compared to the same quarter last year.

Jackson Creek Investment Advisors LLC purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 30,683 shares of the company's stock, valu

Harmony Biosciences (NASDAQ:HRMY) Shares Gap Up to $29.25

Needham & Company LLC reaffirmed a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday.